Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(3 years from now) | |
US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6723340 | JANSSEN PHARMS | Optimal polymer mixtures for gastric retentive tablets |
Oct, 2021
(2 years ago) | |
US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(3 months from now) | |
US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(11 months from now) |
Invokamet Xr is owned by Janssen Pharms.
Invokamet Xr contains Canagliflozin; Metformin Hydrochloride.
Invokamet Xr has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Invokamet Xr are:
Invokamet Xr was authorised for market use on 20 September, 2016.
Invokamet Xr is available in tablet, extended release;oral dosage forms.
Invokamet Xr can be used as reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients, reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients.
Drug patent challenges can be filed against Invokamet Xr from 29 March, 2017.
The generics of Invokamet Xr are possible to be released after 26 February, 2029.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Aug 08, 2017 |
New Indication(I-735) | May 20, 2019 |
New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 20 September, 2016
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reductio...
Dosage: TABLET, EXTENDED RELEASE;ORAL